Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
|Articles|January 2, 2011
- Pharmaceutical Technology-01-02-2011
- Volume 35
- Issue 1
Pharmaceutical Technology, January 2011 Issue (PDF)
Outlook 2011
Advertisement
Articles in this issue
over 15 years ago
Global Healthcare on the Ground: Global Health Progress Initiativeover 15 years ago
Exploring Custom Synthesisover 15 years ago
Report from Europeover 15 years ago
Inside ICH: ICH Meets in Japan to Finalize Key Documentsover 15 years ago
In the Spotlight January 2011over 15 years ago
Outlook 2011over 15 years ago
A Comparison of Three Extrusion Systemsover 15 years ago
Cost and Compliance Dominate Agenda for 2011over 15 years ago
Improving the Quality of Product ReleaseAdvertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement